Sanofi
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
FDA to review Sanofi, Regeneron's Dupixent sBLA for CSU
FDA reviews Sanofi and Regeneron’s Dupixent for chronic spontaneous urticaria (CSU) in adults and children aged 12+ despite H1 antihistamine treatment, with a decision target date of 18 April 2025. Based on LIBERTY-CUPID Phase III clinical programme, Dupixent showed significant itch and urticaria activity reduction, with a consistent safety profile. Dupixent is approved in over 60 countries for various conditions and is under review in the EU for CSU.
FDA accepts application for dupilumab to treat chronic spontaneous urticaria
FDA accepts dupilumab's sBLA for chronic spontaneous urticaria treatment, targeting April 18, 2025 for approval. Dupilumab, an IL-4 and IL-13 inhibitor, aims to treat CSU not controlled by H1 antihistamines. Studies A, B, and C in the LIBERTY-CUPID program support the application, showing dupilumab's efficacy in reducing itch and urticaria activity.
EMA's CHMP recommends Sanofi's Sarclisa approval for multiple myeloma
EMA’s CHMP recommends Sanofi’s Sarclisa with VRd for newly diagnosed MM in transplant-ineligible patients, based on Phase III IMROZ trial results. Sarclisa, approved in over 50 countries for relapsed or refractory MM, shows no new safety concerns when combined with VRd. Sanofi aims to establish a new standard-of-care in the EU.
Halozyme Makes Unsolicited €2B Takeover Bid for Drug R&D Services Firm Evotec
Halozyme proposes €2 billion acquisition of Evotec, offering €11.00 per share in cash, a 109% premium to Evotec's Oct. 15 stock price. Evotec, with 4,000 employees, faces recent setbacks including a cyberattack and restructuring. Halozyme, with 373 employees, offers Enhanze drug delivery tech used by Roche, Takeda, Eli Lilly, Pfizer, and AbbVie.
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic
FDA accepts Regeneron and Sanofi's resubmission of Dupixent for chronic spontaneous urticaria (CSU) review, with a decision expected by April 18, 2025. Dupixent, if approved, would be the first targeted therapy for CSU in a decade, supported by pivotal data showing significant itch and hive activity reduction.
FDA reviews Sanofi and Regeneron's Dupixent label expansion for urticaria
FDA reviews Sanofi and Regeneron’s Dupixent for chronic spontaneous urticaria, targeting decision by April 2025. Dupixent, a monoclonal antibody, inhibits IL-4 and IL-13 pathways, showing significant itch and urticaria reduction in Study C. Already approved in Japan and UAE, Dupixent seeks EU approval and has potential revenue of $23.6bn by 2030.
Related Clinical Trials:
Promising hepatitis B treatment data presented by Vir Biotechnology
Vir Biotechnology's Phase 2 trial for chronic hepatitis B treatment showed significant HBsAg loss rates with tobevibart and elebsiran, with or without pegylated interferon alfa. The company aims for a functional cure by Q2 2025, with ongoing progress in hepatitis programs and T-cell engager trials. Financial stability and strategic restructuring support continued R&D efforts despite revenue challenges.
BioNTech to acquire Chinese oncology startup for almost US$1bn
BioNTech acquires Chinese oncology startup Biotheus for $950m to develop BNT327/PM8002 antibody, aiming to enhance oncology treatment portfolio and expand in China.
FDA Sets Date For Resubmitted Dupixent in Inflammatory Skin Disease
The FDA accepted the resubmission of Dupixent's sBLA for treating chronic spontaneous urticaria in adults and patients aged 12+; target action date is April 18, 2025. Dupixent, developed by Regeneron and Sanofi, inhibits IL-4 and IL-13 pathways and is approved for multiple indications. The resubmission includes data from Study C, showing Dupixent significantly reduced itch and urticaria activity in patients with uncontrolled CSU on antihistamines.
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the
FDA accepts Regeneron and Sanofi's resubmission of sBLA for Dupixent to treat chronic spontaneous urticaria (CSU) in adults and pediatric patients aged 12 and older, with a decision expected by April 18, 2025. The resubmission includes pivotal data confirming Dupixent's significant reduction in itch and hive activity, supported by the LIBERTY-CUPID Phase 3 clinical program. If approved, Dupixent would be the first targeted therapy for CSU in a decade.
© Copyright 2025. All Rights Reserved by MedPath